Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The primary objectives of this prospective mixed-method interview study are to use semi-structured interviews in parents of sickle cell disease (SCD) patients to describe parental attitudes of research involving genomic sequencing, including concerns about participation and expectations from researchers and second, to use surveys to quantitatively measure genetic/genomic knowledge, trust in health care provider, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD. Secondary objectives are development of a web-based tool about treatment options for SCD that fosters patient-clinician communication and promotes shared decision-making. The web-based tool will undergo usability and pilot testing to ensure it is accessible to families and provide data about strategies for integrating into clinical conversations about treatment options. Investigators will use the data generated to reduce the risk of misunderstanding about DNA and genetic research and build strong relationships between SCD families and researchers in the future. The project will design educational information and study materials to help parents of children with SCD understand important details about genomic medicine in SCD care.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 13
Healthy Volunteers: t
View:

⁃ Group 1 (Survey and Interview) Participants only:

• Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13-18 with aforementioned SCD genotype.

• Informed consent from parent or legal guardian and assent of adolescent participant.

• Has been previously approached for SCRIPP.

⁃ Group 2 (Usability and Pilot Testing) Participants only:

• Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13 and up with aforementioned SCD genotype.

• Informed consent from parent or legal guardian and assent of adolescent participant.

Locations
United States
Tennessee
St. Jude Children's Research Hospital
RECRUITING
Memphis
Contact Information
Primary
Liza M. Johnson, MD, MPH, MSB
referralinfo@stjude.org
866-278-5833
Time Frame
Start Date: 2020-12-17
Estimated Completion Date: 2026-12
Participants
Target number of participants: 352
Treatments
Survey and Interview Group (Group1)
Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13-18 with aforementioned SCD genotype.
Usability and Pilot Testing (Group 2)
Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13 and up with aforementioned SCD genotype.
Sponsors
Leads: St. Jude Children's Research Hospital
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials